Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Day: August 4, 2025

Onco_background

Oncology Weekly News - August 4th 2025

🔬🧬 Oncology Updates: Ivonescimab Approved, Imfinzi Fast Tracked, TEVIMBRA EU…

Hematology

Hematology Weekly News - August 4th 2025

🔬🧬 Hematology Updates: Sanofi’s Myeloma Win, AI in Lymphoma, SCD Breakthrough…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Cardiovascular Today—April 2, 2026
Cell and Gene Therapy Today—April 2, 2026
Rare Diseases Today—April 2, 2026

Tags

AI-native clinical development AMXT 1501 Baseimmune Chronic disease mortality conduction-system pacing cost reduction CUF CytomX Therapeutics Dersimelagon dialysis DIPS Arena Dizal Emboline Enzalutamide FDA Digital Health Advisory FG001 FIGO Gazyvaro Glanzmann Thrombasthenia GLP-1 Receptor Agonists glycosylation gout flares Hong Kong biotech Jaypirca live biotherapeutic product Merck Animal Health MicroRNAs naxtarubicin OCALIVA Pediatric Cancers PPMS QRX003 ralinepag Receptor.AI Rinvoq Rituximab SNV4818 Spikevax Stanford Medicine Sutra Medical TG Therapeutics Transgene UPATHLN Ver-A-T1D Welireg

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Cardiovascular Today—April 2, 2026
Cell and Gene Therapy Today—April 2, 2026
Rare Diseases Today—April 2, 2026

TAGS

AI-native clinical development AMXT 1501 Baseimmune Chronic disease mortality conduction-system pacing cost reduction CUF CytomX Therapeutics Dersimelagon dialysis DIPS Arena Dizal Emboline Enzalutamide FDA Digital Health Advisory FG001 FIGO Gazyvaro Glanzmann Thrombasthenia GLP-1 Receptor Agonists glycosylation gout flares Hong Kong biotech Jaypirca live biotherapeutic product Merck Animal Health MicroRNAs naxtarubicin OCALIVA Pediatric Cancers PPMS QRX003 ralinepag Receptor.AI Rinvoq Rituximab SNV4818 Spikevax Stanford Medicine Sutra Medical TG Therapeutics Transgene UPATHLN Ver-A-T1D Welireg

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy